Subtype
Head and Neck Carcinoma
CI-CAN-00000950Explore in graph →
1,013 active trials15 approved drugs119 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000950Explore in graph →
Clinical trials
2,921 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (347)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03524326 | Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma | completed | Phase 1 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT03212469 | A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer(ABIMMUNE) | completed | Phase 1 / Phase 2 | 54 | Gustave Roussy, Cancer Campus, Grand ParisOTHER |
| 1 |
| May 8, 2025 |
| clinicaltrials |
| NCT04925284 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | completed | Phase 1 | 269 | ExelixisINDUSTRY | 9 | Apr 4, 2025 | clinicaltrials |
| NCT03894618 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 49 | Shattuck Labs, Inc.INDUSTRY | 4 | Apr 2, 2025 | clinicaltrials |
| NCT05410821 | Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Metastatic Radioactive Iodine Refractory Thyroid Cancer | completed | Phase 1 | 12 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT04830592 | A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck(MOAT) | completed | Phase 1 | 36 | Akamis BioINDUSTRY | 1 | Mar 24, 2025 | clinicaltrials |
| NCT03195699 | Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers | completed | Phase 1 | 64 | Tvardi Therapeutics, IncorporatedINDUSTRY | 1 | Mar 21, 2025 | clinicaltrials |
| NCT04091867 | sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC | completed | Phase 1 | 3 | University of Colorado, DenverOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT02381535 | Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin | completed | Phase 1 | 2 | National Cancer Institute (NCI)NIH | 2 | Feb 11, 2025 | clinicaltrials |
| NCT01638533 | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction | completed | Phase 1 | 37 | National Cancer Institute (NCI)NIH | 2 | Feb 7, 2025 | clinicaltrials |
| NCT05053737 | Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV Unrelated HNSCC | completed | Phase 1 | 11 | University of Colorado, DenverOTHER | 1 | Feb 3, 2025 | clinicaltrials |
| NCT04815720 | Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck(KEYNOTE-B84) | completed | Phase 1 / Phase 2 | 49 | Vaccinex Inc.INDUSTRY | 1 | Jan 8, 2025 | clinicaltrials |
| NCT04731467 | A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 79 | Famewave Ltd.INDUSTRY | 3 | Dec 27, 2024 | clinicaltrials |
| NCT03997968 | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 169 | Cyteir Therapeutics, Inc.INDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT02538510 | Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery | completed | Phase 1 / Phase 2 | 50 | University of WashingtonOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT02113878 | Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck | completed | Phase 1 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT04096638 | Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors | completed | Phase 1 | 61 | invoX Pharma LimitedINDUSTRY | 1 | Oct 31, 2024 | clinicaltrials |
| NCT04870840 | Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer | completed | Phase 1 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT03028766 | WEE1 Inhibitor with Cisplatin and Radiotherapy: a Trial in Head and Neck Cancer(WISTERIA) | completed | Phase 1 | 9 | University of BirminghamOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04474470 | A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer | completed | Phase 1 / Phase 2 | 52 | TyrNovo Ltd.INDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT04721223 | JAB-3068 Activity in Adult Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 12 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06095362 | Thyroid Cancer and Central Lymph Node Metastases Detection Using Bevacizumab-IRDye800CW(TARGET-beva) | completed | Phase 1 | 20 | University Medical Center GroningenOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT00655655 | Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 96 | Mayo ClinicOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT01847326 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer | completed | Phase 1 | 48 | University of ChicagoOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT03752398 | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)(DUET-3) | completed | Phase 1 | 198 | Xencor, Inc.INDUSTRY | 1 | Jul 5, 2024 | clinicaltrials |
| NCT05538572 | A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors | completed | Phase 1 | 22 | Prelude TherapeuticsINDUSTRY | 2 | Jul 1, 2024 | clinicaltrials |
| NCT05578820 | Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid | completed | Phase 1 | 21 | Gene Surgery LLCINDUSTRY | 1 | Jul 1, 2024 | clinicaltrials |
| NCT03629756 | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | completed | Phase 1 | 48 | Arcus Biosciences, Inc.INDUSTRY | 2 | May 24, 2024 | clinicaltrials |
| NCT05864924 | A Phase 1 Study of BRG01 in Subjects With Relapsed/Metastatic Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma | completed | Phase 1 | 14 | BioSyngen Pte LtdINDUSTRY | 1 | May 8, 2024 | clinicaltrials |
| NCT03470259 | Precision Thyroid Cancer Surgery With Molecular Fluorescent Guided Imaging(TARGET) | completed | Phase 1 | 19 | University Medical Center GroningenOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT03590054 | Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies | completed | Phase 1 | 35 | Rahul AggarwalOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT03665285 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 109 | NextCure, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT02244463 | A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer | completed | Phase 1 / Phase 2 | 46 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT02718820 | Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer | completed | Phase 1 / Phase 2 | 22 | Medical University of ViennaOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT03749460 | Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers | completed | Phase 1 / Phase 2 | 20 | University of WashingtonOTHER | 1 | Dec 29, 2023 | clinicaltrials |
| NCT01709435 | Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 2 | Dec 22, 2023 | clinicaltrials |
| NCT03219268 | A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms | completed | Phase 1 | 277 | MacroGenicsINDUSTRY | 8 | Dec 21, 2023 | clinicaltrials |
| NCT03454451 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | completed | Phase 1 | 117 | Corvus Pharmaceuticals, Inc.INDUSTRY | 2 | Dec 21, 2023 | clinicaltrials |
| NCT03229278 | Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma | completed | Phase 1 | 14 | Rutgers, The State University of New JerseyOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT02178436 | Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 15 | Mohammed Najeeb Al HallakOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT03735628 | An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors | completed | Phase 1 | 16 | BayerINDUSTRY | 2 | Oct 6, 2023 | clinicaltrials |
| NCT04601402 | GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy | completed | Phase 1 | 11 | Genome & CompanyINDUSTRY | 1 | Aug 8, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT04929080 | The Safety and Efficacy of Multiple-dose of JS004 in Subject With HNC | completed | Phase 1 / Phase 2 | 149 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT04452214 | A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors | completed | Phase 1 | 19 | Cantargia ABINDUSTRY | 1 | Jul 14, 2023 | clinicaltrials |
| NCT01835041 | CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer | completed | Phase 1 | 21 | Wake Forest University Health SciencesOTHER | 1 | Jul 12, 2023 | clinicaltrials |
| NCT04572100 | Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer | completed | Phase 1 | 50 | University of ChicagoOTHER | 1 | Jul 7, 2023 | clinicaltrials |
| NCT03829436 | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers | completed | Phase 1 | 38 | Tempest TherapeuticsINDUSTRY | 1 | Jul 3, 2023 | clinicaltrials |
| NCT02949700 | Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma | completed | Phase 1 / Phase 2 | 26 | Baylor College of MedicineOTHER | 1 | Jun 29, 2023 | clinicaltrials |
Data updated 22 days agoSource updated May 13, 2025source: clinicaltrials